Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

Purpose: Adoptive cell transfer (ACT) of tumor infiltrating or genetically engineered T cells can cause durable responses in patients with metastatic cancer. Multiple clinically modifiable parameters can comprise this therapy, including cell dose and phenotype, in vivo antigen restimulation, and common gamma-chain (γc) cytokine support. However, the relative contributions of each these individual components to the magnitude of the antitumor response have yet to be quantified. Experimental Design: To systematically and quantitatively appraise each of these variables, we employed the Pmel-1 mouse model treating large, established B16 melanoma tumors. In addition to cell dose and magnitude of in vivo antigen restimulation, we also evaluated the relative efficacy of central memory (TCM), effector memory (TEM), and stem cell memory (TSCM) subsets on the strength of tumor regression as well as the dose and type of clinically available γc cytokines, including IL-2, IL-7, IL-15, and IL-21. Results: We found that cell dose, T-cell differentiation status, and viral vaccine titer each were correlated strongly and significantly with the magnitude of tumor regression. Surprisingly, although the total number of IL-2 doses was correlated with tumor regression, no significant benefit to prolonged (≥6 doses) administration was observed. Moreover, the specific type and dose of γc cytokine only moderately correlated with response. Conclusion: Collectively, these findings elucidate some of the key determinants of successful ACT immunotherapy for the treatment of cancer in mice and further show that γc cytokines offer a similar ability to effectively drive antitumor T-cell function in vivo. Clin Cancer Res; 17(16); 5343–52. ©2011 AACR.

[1]  D. Kranz.  Faculty Opinions recommendation of A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. , 2011 .

[2]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[3]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Burns,et al.  Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. , 2011, Blood.

[6]  C. Klebanoff,et al.  Therapeutic cancer vaccines: are we there yet? , 2011, Immunological reviews.

[7]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[8]  S. H. van der Burg,et al.  Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. , 2010, Cancer research.

[9]  S. Rosenberg,et al.  CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma , 2010, Clinical Cancer Research.

[10]  Richard A. Morgan,et al.  A Simplified Method for the Clinical-scale Generation of Central Memory-like CD8+ T Cells After Transduction With Lentiviral Vectors Encoding Antitumor Antigen T-cell Receptors , 2010, Journal of immunotherapy.

[11]  M. Sadelain,et al.  IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. , 2010, Blood.

[12]  B. Shalmon,et al.  Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients , 2010, Clinical Cancer Research.

[13]  M. Sadelain,et al.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  H. Heslop,et al.  Adoptive T cell therapy of cancer. , 2010, Current opinion in immunology.

[15]  P. Darcy,et al.  Enhancing adoptive immunotherapy of cancer , 2010, Expert opinion on biological therapy.

[16]  S. Steinberg,et al.  Phase I Study of Recombinant Human Interleukin-7 Administration in Subjects with Refractory Malignancy , 2010, Clinical Cancer Research.

[17]  S. Rosenberg,et al.  Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells , 2010, Journal of immunotherapy.

[18]  S. Ugel,et al.  In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. , 2009, Cancer research.

[19]  M. Sadelain.  T-cell engineering for cancer immunotherapy. , 2009, Cancer journal.

[20]  S. Rosenberg,et al.  Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. , 2009, Journal of immunotherapy.

[21]  S. Riddell,et al.  Safety and immunologic effects of IL-15 administration in nonhuman primates. , 2009, Blood.

[22]  C. Klebanoff,et al.  Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. , 2009, Blood.

[23]  W. Overwijk,et al.  Functions of γC cytokines in immune homeostasis: current and potential clinical applications. , 2009, Clinical immunology.

[24]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[25]  P. Muranski,et al.  Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.

[26]  E. Segal,et al.  Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients , 2009, Journal of immunotherapy.

[27]  J. Wolchok,et al.  Self-antigen–specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response , 2009, The Journal of experimental medicine.

[28]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[30]  S. Rosenberg,et al.  Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy , 2008, Journal of immunotherapy.

[31]  T. Schumacher,et al.  Requirements for Effective Antitumor Responses of TCR Transduced T Cells1 , 2008, The Journal of Immunology.

[32]  Jinjuan Wang,et al.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.

[33]  J. Ritz,et al.  Targets of Tumor Immunity After Allogeneic Hematopoietic Stem Cell Transplantation , 2008, Clinical Cancer Research.

[34]  T. Schumacher,et al.  TCR Gene Therapy of Spontaneous Prostate Carcinoma Requires In Vivo T Cell Activation1 , 2008, The Journal of Immunology.

[35]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[36]  S. Rosenberg,et al.  Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity , 2008, Proceedings of the National Academy of Sciences.

[37]  W. Leonard,et al.  IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. , 2008, Blood.

[38]  C. Melief,et al.  Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines , 2008, Nature Reviews Cancer.

[39]  B. Redman,et al.  Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  H. Heslop,et al.  Adoptive cellular immunotherapy for viral diseases , 2008, Bone Marrow Transplantation.

[41]  G. McArthur,et al.  An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma , 2007, Clinical Cancer Research.

[42]  S. Rosenberg,et al.  Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. , 2007, The Journal of clinical investigation.

[43]  T. Waldmann,et al.  The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells , 2007, Proceedings of the National Academy of Sciences.

[44]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[45]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[46]  C. Klebanoff,et al.  CD8+ T‐cell memory in tumor immunology and immunotherapy , 2006, Immunological reviews.

[47]  S. Rosenberg,et al.  IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells , 2006, Journal of immunotherapy.

[48]  C. Klebanoff,et al.  Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo1 , 2006, The Journal of Immunology.

[49]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[50]  S. Rosenberg,et al.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells , 2005, The Journal of experimental medicine.

[51]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[53]  T. Fry,et al.  Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. , 2005, The Journal of clinical investigation.

[54]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  C. Klebanoff,et al.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. , 2005, Trends in immunology.

[56]  J. Berzofsky,et al.  Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function , 2005, The Journal of experimental medicine.

[57]  S. Rosenberg,et al.  Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .

[58]  P. Hwu,et al.  Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo , 2004, Cancer Research.

[59]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[60]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[61]  T. Waldmann,et al.  IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells , 2002 .

[62]  T. Waldmann,et al.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. , 2002, Immunity.

[63]  S. Steinberg,et al.  Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  F. Marincola,et al.  Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.